Table 1.

Study Design for Included Trials

Study Clinicaltrials.gov Identifier	Active Intervention	Primary Efficacy Endpoint(s)	Secondary Efficacy Endpoint(s)	Number Randomized, Number in mITT	Number Randomized/Number Treatment Groups
ACHIEVE I8 NCT02828020	Ubrogepant 50 mg†	2‐hour headache freedom 2‐hour MBS freedom	2‐24 hours sustained pain freedom 2‐hour pain relief 2‐24 hours sustained pain relief Absence/presence of individual non‐headache migraine symptoms‡ at 2 hours9	1672, 1327	557
ACHIEVE II7 NCT02867709	Ubrogepant 50 mg§	2‐hour headache freedom 2‐hour MBS freedom	2‐24 hours sustained pain freedom 2‐hour pain relief 2‐24 hours sustained pain relief Absence/presence of individual non‐headache migraine symptoms‡ at 2 hours9	1686, 1355	562
RESTOR6 NCT02569853	DFN‐11 (Sumatriptan injection 3 mg)	2‐hour headache freedom	2‐hour MBS freedom Pain freedom at earlier postdose time points	268, NR	134
SPARTAN10 NCT02605174	Lasmitidan 200 mg¶	2‐hour headache freedom 2‐hour MBS freedom	2‐hour pain relief 2‐hour headache recurrence 2‐hour use of rescue medication 24‐hour use of rescue medication Absence of individual non‐headache migraine symptoms‡ at 2 hours9	3005, 2156	751
SAMURAI11 NCT02439320	Lasmitidan 200 mg‡	2‐hour headache freedom 2‐hour MBS freedom	2‐hour pain relief, 2‐hour headache recurrence 2‐hour use of rescue medication 24‐hour use of rescue medication Absence of individual non‐headache migraine symptoms‡ at 2 hours9	2232‡,12 NR	743
Study 30113 NCT03235479	Rimegepant 75 mg	2‐hour headache freedom 2‐hour MBS freedom	2‐24 hours sustained pain freedom 2‐hour pain relief 24‐hour use of rescue medication 2‐24 hours sustained pain freedom Absence of individual non‐headache migraine symptoms† at 2 hours 2‐24 and 2‐48 hours sustained pain relief 2 hours functional disability score, 2‐48 hours pain relapse9	1162, 1084	581
Study 30214 NCT03237845	Rimegepant 75 mg	2‐hour headache freedom 2‐hour MBS freedom	2‐24 hours sustained pain freedom 2‐hour pain relief 24‐hour use of rescue medication 2‐24 hours sustained pain freedom Absence of individual non‐headache migraine symptoms‡ at 2 hours 2‐24 and 2‐48 hours sustained pain relief 2‐hour functional disability score 2‐48 hours pain relapse9	1186, 1072	593
ZOTRIP15	ADAM zolmitriptan 3.8 mg‡	2‐hour headache freedom 2‐hour MBS freedom	0.25‐4 hours pain relief 0.5‐40 hours pain freedom Absence of individual non‐headache migraine symptoms‡ at 2 hours Use of rescue medication during the 2 hours postdose period	365, 360	91

^†Additional dose was 100 mg.

^‡Photophobia, phonophobia, nausea.

^§Additional dose was 25 mg.

^¶Additional doses were 100 mg, 50 mg.

^**Additional dose was 100 mg.

^††Enrolled.

^‡‡Additional doses were 1 mg, 1.9 mg.

MBS = most bothersome symptom; mITT = modified intent to treat population; NR = not reported.